
Claims

1. Compounds according to formula (I),



(I)

wherein R_1 is a group selected from among -H, -halogen, -CN, -O-C_1-C_4-alkyl, -C_1-C_4-alkyl, -CH=CH_2, -C≡CH, -CF_3, -OCF_3, -OCF_2H, and -$OCFH_2$;

wherein R_7 is a ring selected from among -C_3-C_8-cycloalkyl, -C_3-C_8-heterocyclyl, -C_5-C_{10}-aryl, and -C_5-C_{10}-heteroaryl,
wherein the ring R_7 is optionally substituted with one or more groups selected from among -CF_3, -O-CF_3, -S-CF_3, -CN, -C_1-C_6-alkyl,-$C(CH_3)_2$-CN, and -halogen,
or wherein the ring R_7 is optionally substituted with one or more groups selected from among -C_1-C_6-alkyl, -O-C_1-C_6-alkyl, -C_5-C_{10}-aryl, -C_5-C_{10}-heteroaryl, -C_3-C_8-cycloalkyl, -C_3-C_8-heterocyclyl, -C_2-C_6-alkenyl, and -C_2-C_6-alkynyl, optionally being substituted by one or more groups selected from among -OH, -NH_2, -C_1-C_3-alkyl, -O-C_1-C_6-alkyl, -CN, -CF_3, -OCF_3, halogen, -methyl, and =O,
or wherein the ring R_7 is optionally further bi-valently substituted on two neighbouring ring atoms, such that an annellated ring is formed by one or more groups selected from among -C_1-C_6-alkylene, -C_2-C_6-alkenylene and -C_4-C_6-alkynylene, in which one or two or three carbon centers may optionally be replaced by 1 or 2 or 3 hetero atoms selected from N, O and S, the bivalent group being optionally substituted by one or more groups selected from -OH, -NH_2, -C_1-C_3-alkyl, -O-C_1-C_6-alkyl, -CN, -CF_3, -OCF_3, halogen, and =O;

wherein R_2 is selected from among -H, -halogen, -CN, -O-C_2-C_4-alkyl, -C_1-C_4-alkyl, -CH=CH_2, -C≡CH, -CF_3, -OCF_3, -OCF_2H, and -$OCFH_2$;

wherein R_3 is selected from among -H, -methyl, -ethyl, -propyl, -i-propyl, -cyclopropyl, -OCH_3, -CF_3, and –CN;

wherein n is 1, 2 or 3;

wherein G and E are independently selected from among C-H or N;

wherein Z is C,
and R_4 and R_5 are independently selected from among -H, -C_1-C_6-alkyl, -NH_2, -C_3-C_8-cycloalkyl, -C_3-C_8-heterocyclyl, -C_5-C_{10}-aryl, -C_5-C_{10}-heteroaryl, and -C(O)-N(R_8,$R_{8'}$), with R_8 and $R_{8'}$ independently being selected from among -H, and -C_1-C_6-alkyl,

or wherein Z is N,
and R_4 denotes an electron pair and R_5 is selected from among -H, -C_1-C_6-alkyl, -NH_2, -C_3-C_8-cycloalkyl, -C_3-C_8-heterocyclyl, -C_5-C_{10}-aryl, -C_5-C_{10}-heteroaryl, and -C(O)-N(R_8,$R_{8'}$), with R_8 and $R_{8'}$ independently being selected from among -H, and -C_1-C_6-alkyl,

and wherein R_4 and R_5 if different from an electron pair or -H are optionally independently substituted with one or more groups selected from among -halogen, -OH, -CF_3, -CN, -C_1-C_6-alkyl, -O-C_1-C_6-alkyl, -O-C_3-C_8-cycloalkyl, -O-C_3-C_8-heterocyclyl, -O-C_5-C_{10}-aryl, -O-C_5-C_{10}-heteroaryl, -C_0-C_6-alkylene-CN, -C_0-C_4-alkylene-O-C_1-C_4-alkyl, -C_0-C_4-alkylene-O-C_3-C_8-cycloalkyl, -C_0-C_4-alkylene-O-C_3-C_8-heterocyclyl, -C_0-C_4-alkylene-O-C_5-C_{10}-aryl, -C_0-C_4-alkylene-O-C_5-C_{10}-heteroaryl, -C_0-C_4-alkylene-Q-C_0-C_4-alkyl-N(R_9,$R_{9'}$), -C_0-C_4-alkylene-N(R_{10})-Q-C_1-C_4-alkyl, -C_0-C_4-alkylene-N(R_{10})-Q-C_3-C_8-cycloalkyl, -C_0-C_4-alkylene-N(R_{10})-Q-C_3-C_8-heterocyclyl, -C_0-C_4-alkylene-N(R_{10})-Q-C_5-C_{10}-aryl, -C_0-C_4-alkylene-N(R_{10})-Q-C_5-C_{10}-heteroaryl, -C_0-C_4-alkylene-Q-N(R_{11},$R_{11'}$), -C_0-C_4-alkylene-N(R_{12})-Q-N(R_{13},$R_{13'}$), -C_0-C_4-alkylene-R_{14}, -C_0-C_4-alkylene(R_{20},$R_{20'}$), -C_0-C_4-alkylene-Q-C_1-C_6-alkyl, -C_0-C_4-alkylene-Q-C_3-C_8-cycloalkyl, -C_0-C_4-alkylene-Q-C_3-C_8-heterocyclyl, -C_0-C_4-alkylene-Q-C_5-C_{10}-aryl, -C_0-C_4-alkylene-Q-C_5-C_{10}-heteroaryl, -C_0-C_4-alkylene-O-Q-N(R_{15},$R_{15'}$), and -C_0-C_4-alkylene-N(R_{16})-Q-O-(R_{17}),
wherein Q is selected from among -C(O)-, and -SO_2-,
wherein R_{10}, R_{12}, R_{16}, are independently selected from among -H, -C_1-C_6-alkyl, and -C_3-C_6-cycloalkyl,
wherein R_9, $R_{9'}$, R_{11}, $R_{11'}$, R_{13}, $R_{13'}$, R_{15}, $R_{15'}$, are independently selected from among -H, -C_1-C_6-alkyl, and -C_3-C_6-cycloalkyl,
or wherein R_9 and $R_{9'}$, R_{11} and $R_{11'}$, R_{13} and $R_{13'}$, R_{15} and $R_{15'}$ together form a -C_2-C_6-alkylene group,
wherein R_{14} and R_{17} are independently selected from among -H, -C_1-C_6-alkyl, -C_5-C_{10}-aryl, -C_5-C_{10}-heteroaryl, -C_3-C_8-cycloalkyl, and -C_3-C_8-heterocyclyl, wherein said -C_3-C_8-heterocyclyl optionally comprises nitrogen and/or -SO_2- in the ring,

and wherein R_{14} and R_{17} are optionally substituted with one or more groups selected from among -OH, $-OCH_3$, $-CF_3$, -COOH, $-OCF_3$, -CN, -halogen, $-C_1$-C_4-alkyl, =O, and $-SO_2$-C_1-C_4-alkyl,
wherein R_{20} and $R_{20'}$ together form a spiro-C_3-C_8-carbocycle or spiro-C_3-C_8-heterocycle comprising one or more group selected from O in the ring, and wherein said spirocycle is optionally further bi-valently substituted by an annellated ring forming group selected from among $-C_1$-C_6-alkylene, $-C_2$-C_6-alkenylene, and $-C_4$-C_6-alkynylene and wherein said spirocycle is optionally further substituted with one or more groups selected from among -OH, $-OCH_3$, $-CF_3$, -COOH, $-OCF_3$, -CN, -halogen,

or wherein Z is C,
and R_4 denotes –H and R_5 is a group of the structure $-L_1$-R_{18},
wherein L_1 is selected from among -NH-, -N(C_1-C_4-alkyl)-, and a bond,
wherein R_{18} is selected from among -C_5-C_{10}-aryl, -C_5-C_{10}-heteroaryl, -C_3-C_8-cycloalkyl, and -C_3-C_8-heterocyclyl,
wherein R_{18} is optionally substituted by one or more groups selected from among halogen, $-CF_3$, $-OCF_3$, -CN, -OH, -O-C_1-C_4-alkyl, -C_1-C_6-alkyl, -NH-C(O)-C_1-C_6-alkyl, -N(C_1-C_4-alkyl)-C(O)-C_1-C_6-alkyl, -C(O)-C_1-C_6-alkyl, -$S(O)_2$-C_1-C_6-alkyl, -NH-$S(O)_2$-C_1-C_6-alkyl, -N(C_1-C_4-alkyl)-$S(O)_2$-C_1-C_6-alkyl, and -C(O)-O-C_1-C_6-alkyl,
and wherein R_4, R_5 and R_{18} are optionally further substituted by spiro-C_3-C_8-cycloalkyl or spiro-C_3-C_8-heterocyclyl such that together with R_4, R_5 and/or R_{18} a spirocycle is formed, wherein said spiro-C_3-C_8-heterocyclyl optionally comprises one or more groups selected from among nitrogen, -C(O)-, $-SO_2$-, and -N(SO_2-C_1-C_4-alkyl)- in the ring,
or wherein R_4, R_5 and R_{18} are optionally further bi-valently substituted by one or more spirocyclic or annellated ring forming groups selected from among $-C_1$-C_6-alkylene, $-C_2$-C_6-alkenylene, and $-C_4$-C_6-alkynylene, in which one or two carbon centers may optionally be replaced by one or two hetero atoms selected from among N, O and S and which may optionally be substituted by one or more groups on one ring atom or on two neighbouring ring atoms selected from among -OH, $-NH_2$, $-C_1$-C_3-alkyl, -O-C_1-C_6-alkyl, -CN, $-CF_3$, $-OCF_3$, and halogen;

wherein R_6 is selected from among -H, $-C_1$-C_4-alkyl, -OH, -O-C_1-C_4-alkyl, -halogen, -CN, $-CF_3$, and $-OCF_3$;


as well as in form of their acid addition salts with pharmacologically acceptable acids.




2. The compounds of of claim 1,

wherein Z is C,

and R_4 and R_5 are independently selected from among -H, -i-propyl, -amino, -pyrrolidinyl, -piperidinyl, -morpholinyl, -azepanyl, -oxazepanyl, -piperazinyl, -azetidinyl, -tetrahydropyranyl, -cyclopentyl, -cyclohexyl, and -C(O)-N(R_8,$R_{8'}$), with R_8 and $R_{8'}$ independently being selected from among -H and -C_1-C_6-alkyl,

wherein R_4 and R_5 if different from -H are optionally independently substituted with one or more groups selected from among -fluoro, -methyl, -ethyl, propyl, -i-propyl, -butyl, -i-butyl, -t-butyl, -hydroxy, -CF_3, -OCF_3, -CN, -O-CH_3, -O-C_2H_5, -O-C_3H_7, -CH_2-CN, -CH_2-O-CH_3, -$(CH_2)_2$-O-CH_3, -C(O)-CH_3, -C(O)-C_2H_5, -C(O)-C_3H_7, -COOH, -C(O)-NH_2, -C(O)-NH-CH_3, -C(O)-N(CH_3)$_2$, -NH-C(O)-CH_3, -N(CH_3)C(O)-CH_3, -NH-C(O)-C_2H_5, -N(CH_3)-C(O)-C_2H_5, -NH-C(O)-C_3H_7, -N(CH_3)-C(O)-C_3H_7, -NH-SO_2-CH_3, -N(CH_3)-SO_2-CH_3, -N(C_2H_5)-SO_2-CH_3, -N(C_3H_7)-SO_2-CH_3, -NH-SO_2-C_2H_5, -N(CH_3)-SO_2-C_2H_5, -N(C_2H_5)-SO_2-C_2H_5, -N(C_3H_7)-SO_2-C_2H_5, -NH-SO_2-C_3H_7, -N(CH_3)-SO_2-C_3H_7, -N(C_2H_5)-SO_2-C_3H_7, -N(C_3H_7)-SO_2-C_3H_7, -NH-SO_2-C_3H_5, -N(CH_3)-SO_2-C_3H_5, -N(C_2H_5)-SO_2-C_3H_5, -N(C_3H_7)-SO_2-C_2H_5, -CH_2-NH-SO_2-CH_3, -CH_2-N(CH_3)-SO_2-CH_3, -CH_2-NH-SO_2-C_2H_5, -CH_2-N(CH_3)-SO_2-C_2H_5, -CH_2-NH-SO_2-C_3H_7, -CH_2-N(CH_3)-SO_2-C_3H_7, -CH_2-NH-SO_2-C_3H_5, -CH_2-N(CH_3)-SO_2-C_3H_5, -NH-C(O)-NH_2, -N(CH_3)-C(O)-NH_2, -NH-C(O)-NH-CH_3, -N(CH_3)-C(O)-NH-CH_3, -NH-C(O)-N(CH_3)$_2$, -N(CH_3)-C(O)-N(CH_3)$_2$, -SO_2-NH_2, -SO_2-NH(CH_3), -SO_2-N(CH_3)$_2$, -C(O)-NH-C_2H_5, -C(O)-N(CH_3)-C_2H_5, -C(O)-N(CH_3)-C_3H_7, -C(O)-N(CH_3)-C_4H_9, -C(O)-NH-CH(CH_3)-C_2H_5, -C(O)-N(CH_3)-CH(CH_3)-C_2H_5, -CH_2-C(O)-NH_2, -CH_2-C(O)-NH-CH_3, -CH_2-C(O)-N(CH_3)$_2$, –N(CH_3)-SO_2-N(CH_3)$_2$, -(C_6-aryl)-COOH, -phenyl, -pyridin-4-yl, -CH_2-3-methyl-oxetan-3-yl, -O-1,2-difluoro-phen-5-yl, -O-pyridin-2-yl, -pyrrolidine-2-one-1-yl, -3,5-dimethyl-[1,2,4]triazol-4-yl, 3-methyl-[1,2,4]oxadiazol-5-yl,


,

,

,

and

,

or wherein Z is C,

and R_4 denotes –H and R_5 is a group of the structure –L_1-R_{18},


wherein L_1 is selected from among -NH-, -N(CH_3)-, and -N(C_2H_5)-,

and wherein R_{18} is selected from among -tetrahydropyranyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -cycloheptyl, -cyclooctyl, -pyrrolidinyl, -piperidinyl, -piperazinyl, -morpholinyl, -chromanyl, -octahydro-pyrano- pyrrolyl,

-octahydro-pyrano-pyridinyl, -octahydro-pyrano-oxazinyl, -oxaspirodecanyl, and -tetrahydro-naphthyridinyl,

wherein R_{18} is optionally substituted by one or more groups selected from among -F, -CF_3, -OCF_3, -CN, -OH, -O-CH_3, -CH_3, -NH-C(O)-CH_3, -N(CH_3)-C(O)-CH_3, -C(O)-CH_3, -$S(O)_2$-CH_3, -NH-$S(O)_2$-CH_3, -N(CH_3)-$S(O)_2$-CH_3, -N(CH_3)-$S(O)_2$-CH_2-CH_3, and -C(O)-O-C_2H_5,

and wherein R_4, R_5 and R_{18} are optionally further bi-valently substituted by one or more groups selected from among



on one ring atom or on two neighboring ring atoms, such that spirocyclic or annellated rings are formed.

3. The compounds of any of the preceding claims, wherein R_7 is selected from among -C_5-C_6-aryl, -C_5-C_6-heteroaryl, -C_3-C_8-cycloalkyl, and -C_3-C_8-heterocyclyl

wherein the ring R_7 is optionally substituted with one or more groups selected from among -CF_3, -O-CF_3, -S-CF_3, -CN, -methyl, –$C(CH_3)_2$-CN, and -halogen.

4. The compounds of any of the preceding claims, wherein R_7 is selected from among -C_5-C_6-aryl, and -C_5-C_6-heteroaryl,

wherein the ring R_7 is optionally substituted with one or more groups selected from among -CF_3, -O-CF_3, -S-CF_3, -CN, -methyl, –F, -Cl, –$C(CH_3)_2$-CN, and -Br.

5. The compounds of any of the preceding claims 1, 3, and 4

wherein Z is C,

and R_4 denotes –H and R_5 is a group of the structure –L_1-R_{18},

wherein L_1 is selected from among -NH- , -N(CH_3)- , -N(C_2H_5)- , and a bond,

and wherein R_{18} is selected from among –C_6-heterocyclyl comprising 1 or 2 hetero atoms selected from among N, and O,


and wherein R_{18} is optionally substituted by one or more groups selected from among among -F, -CF_3, -OCF_3, -CN, -OH, -O-CH_3, -CH_3, -NH-C(O)-CH_3, -N(CH_3)-C(O)-CH_3, -C(O)-CH_3, -$S(O)_2$-CH_3, -NH-$S(O)_2$-CH_3, -N(CH_3)-$S(O)_2$-CH_3, -N(CH_3)-$S(O)_2$-CH_2-CH_3, and -C(O)-O-C_2H_5, more preferred wherein R_{18} is


optionally substituted by one or more groups selected from among –F, -O-CH_3, -N(CH_3)-S(O)$_2$-CH_3, most preferred wherein R_{18} is optionally substituted by -O-CH_3,

or wherein Z is C,

and R_4 and R_5 are independently selected from among -H, -C_1-C_6-alkyl, and -N(R_{19},$R_{19'}$), wherein R_{19} and $R_{19'}$ together form a –C_2-C_6-alkylene group, preferably a –C_4-C_5alkylene group such that a ring is formed,


wherein such ring is optionally substituted by one or more groups selected from among among -F, -CF_3, -OCF_3, -CN, -OH, -O-CH_3, -CH_3, -NH-C(O)-CH_3, -N(CH_3)-C(O)-CH_3, -C(O)-CH_3, -S(O)$_2$-CH_3, -NH-S(O)$_2$-CH_3, -N(CH_3)-S(O)$_2$-CH_3, -N(CH_3)-S(O)$_2$-CH_2-CH_3, -(C_6-aryl)-COOH, -C(O)-O-C_2H_5,




, and 

,

more preferred wherein such ring is optionally substituted by one or more groups selected from among -O-CH_3, -NH-S(O)$_2$-CH_3, -(C_6-aryl)-COOH, -N(CH_3)-S(O)$_2$-CH_3,



, and 

,

most preferred wherein such ring is optionally substituted by -N(CH_3)-S(O)$_2$-CH_3.

6. The compounds of any of the preceding claims, wherein R_2 is selected from among -H, -methyl, -ethyl, -propyl, -i-propyl, -butyl, -i-butyl, -t-butyl, -F, -Cl, -Br, -I, -CN, -CH=CH_2, and -C≡CH.

7. The compounds of any of the preceding claims, wherein R_2 is selected from among -H, -Methyl, -Ethyl, and -Br, more preferred wherein R_2 is selected from among -H, and -Methyl, most preferred wherein R_2 denotes –Methyl.

8. The compounds of any of the preceding claims 1 to 5, wherein R_2 denotes –H.

9. The compounds of any of the preceding claims, wherein R_3 is selected from among -H, -CF_3, -O-CH_3, and –methyl, more preferred wherein R_3 is selected from among -H, -O-CH_3, and -methyl, more preferred wherein R_3 denotes -H.

10. The compounds of any of the preceding claims 1 to 8, wherein R_3 denotes $-CF_3$.

11. The compounds of any of the preceding claims, wherein R_6 is selected from among -H, $-CH_3$, $-C_2H_5$, $-O-CH_3$, $-O-C_2H_5$, -F, $-CF_3$, and $-OCF_3$, more preferred wherein R_6 is -H or $-O-CH_3$.

12. The compounds of any of the preceding claims, wherein R_1 is -H.

13. The compounds of any of the preceding claims, wherein n is 2.

14. The compounds of any of the preceding claims, wherein G and E are N.

15. The compounds of any of the preceding claims, wherein Z is C.

16. The compound according to any of the preceding claims as a medicament.

17. Use of a compound of any of claims 1-15 for making a medicament for the treatment of inflammatory diseases more preferred wherein the inflammatory diseases are selected from inflammatory diseases of the respiratory tract, most preferred wherein the diseases are selected from chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

18. Use of a compound of any of claims 1-15 for making a medicament for the treatment of neurologic diseases, preferably for the treatment of pain diseases especially for the treatment of inflammatory and neuropathic pain disease.


19. Use of a compound of any of claims 1-15 for making a medicament for the treatment of immune related diseases, preferably for the treatment of diabetes mellitus.


20. Use of a compound of any of claims 1-15 for making a medicament for the treatment of cardiovascular diseases, preferably for the treatment of peripheral atherosclerotic disease.


21. Use of a compound of any of claims 1-16 for making a medicament for the treatment of diabetic nephropathy.


Claims


1. A compound chosen from the group consisting of



,



,



,



,



,



,



,



,



,



,



,



,



,


,



,


,



,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,





,





,



,



,



,


,



,


,



,




,




,




,




,




,





,





,



,



,



,



,



,



,



,























,




,




,




,





,





,



,



,



,



,



,



,
























,



,



,



,



,



,




























,

,

,

,

,

,

,




,




,




,



,





,





.


2. The compound according to claim 1 chosen from the group consisting of



,



,



,



,



,



,



,



,









,


,


,


,


,


,

,

,

,

,

,

.

3. The compound according to any of the preceding claims for use as a medicament.

4. The compound according to any of claims 1-2 for use in the treatment of osteoarthritis, diabetic nephropathy, low back pain, neuropathic pain or a pain disease.